ChiCTR2600119666 版本V1.0 版本创建时间2026/03/02 11:25:26 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600119666 

最近更新日期:

Date of Last Refreshed on:

2026-03-02 11:25:21 

注册时间:

Date of Registration:

2026-03-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于多模态数据整合的 ICU 患者压力性损伤风险预测模型的构建与研究

Public title:

Development and Validation of an Interpretable Machine Learning-Based Risk Prediction Model for Pressure Injury in Intensive Care Unit Patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于多模态数据整合的 ICU 患者压力性损伤风险预测模型的构建与研究

Scientific title:

Development and Validation of an Interpretable Machine Learning-Based Risk Prediction Model for Pressure Injury in Intensive Care Unit Patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王毅苗  

研究负责人:

王毅苗  

Applicant:

Wang Yimiao 

Study leader:

Wang Yimiao 

申请注册联系人电话:

Applicant telephone:

+86 156 1230 3863

研究负责人电话:

Study leader's telephone:

+86 156 1230 3863

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wym19871213@163.com

研究负责人电子邮件:

Study leader's E-mail:

wym19871213@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河北省张家口市长青路12号

研究负责人通讯地址:

河北省张家口市长青路12号

Applicant address:

No. 12, Changqing Road, Zhangjiakou city, Hebei province

Study leader's address:

No. 12, Changqing Road, Zhangjiakou city, Hebei province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

河北北方学院附属第一医院

Applicant's institution:

The First Affiliated Hospital of Hebei North University

研究负责人所在单位:

河北北方学院附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Hebei North University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

k2025121(临)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

河北北方学院附属第一医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of The First Affiliated Hospital of Hebei North University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-05-06 00:00:00

伦理委员会联系人:

尚小领

Contact Name of the ethic committee:

Shang Xiaoling

伦理委员会联系地址:

河北省张家口市桥西区长青路12号

Contact Address of the ethic committee:

No. 12, Changqing Road, Zhangjiakou city, Hebei province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 313 804 3522

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

河北北方学院附属第一医院

Primary sponsor:

The First Affiliated Hospital of Hebei North University

研究实施负责(组长)单位地址:

河北省张家口市长青路12号

Primary sponsor's address:

No. 12, Changqing Road, Zhangjiakou city, Hebei province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北

市(区县):

Country:

China

Province:

Hebei

City:

单位(医院):

河北北方学院附属第一医院

具体地址:

河北省张家口市长青路12号

Institution
hospital:

The First Affiliated Hospital of Hebei North University

Address:

No. 12, Changqing Road, Zhangjiakou city, Hebei province

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

Target disease:

Pressure Injury

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

本研究的主要目的是构建并验证一个基于可解释机器学习算法的预测模型,用于评估重症监护病房(ICU)患者发生压力性损伤的风险。通过收集临床数据,识别关键风险因素,并评估该模型在预测ICU获得性压力性损伤方面的准确性、校准度和临床实用性。  

Objectives of Study:

The primary objective of this study is to develop and validate an interpretable machine learning-based prediction model for assessing the risk of pressure injury (PI) in Intensive Care Unit (ICU) patients. By collecting clinical data, we aim to identify key risk predictors and evaluate the model's performance in terms of discrimination, calibration, and clinical utility for predicting ICU-acquired PI.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.ICU患者; 2.年龄18-80岁; 3.所有患者(或其法定监护人)在参加研究前均已签署知情同意书; 4.入 ICU 后24 h 内完成系统的全身皮肤评估,依据国际压力性损伤分期标准确认入 ICU 时无压力性损伤; 5.在 ICU 住院期间接受持续的皮肤评估,能够明确判断是否发生ICU 期间新发压力性损伤。

Inclusion criteria

1. ICU patients; 2. Age range: 18 - 80 years old; 3. All patients (or their legal guardians) have signed the informed consent form before participating in the study; 4. A comprehensive skin assessment was conducted within 24 hours after admission to the ICU, and it was confirmed that there was no pressure injury upon admission to the ICU according to the international pressure injury staging criteria; 5. During the hospitalization in the ICU, continuous skin assessment was carried out to clearly determine whether new pressure injuries occurred during the ICU stay.

排除标准:

1.入ICU后未完成规范的压力性损伤评估,导致结局无法判定者; 2.入 ICU 时已存在压力性损伤的患者; 3.ICU住院时长<24h的患者。

Exclusion criteria:

1. Those who did not undergo the standardized assessment for pressure injuries after being admitted to the ICU, resulting in an inability to determine the outcome; 2. Patients who already had pressure injuries upon admission to the ICU; 3. Patients who were hospitalized in the ICU for less than 24 hours.

研究实施时间:

Study execute time:

From 2026-03-01 00:00:00 To 2027-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-03-03 00:00:00 To 2026-05-31 00:00:00  

干预措施:

Interventions:

组别:

压力性损伤观察组

样本量:

500

Group:

Pressure injury observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China 

Province:

Hebei 

City:

 

单位(医院):

河北北方学院附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Hebei North University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

ICU获得性压力性损伤的发生

指标类型:

主要指标

Outcome:

Occurrence of ICU-acquired Pressure Injury

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Braden评分

指标类型:

次要指标

Outcome:

Braden Scale for Predicting Pressure Sore Risk

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

急性生理学与慢性健康状况评分II

指标类型:

次要指标

Outcome:

Acute Physiology and Chronic Health Evaluation II

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究使用了一种标准化的纸质病例报告表,该表专为数据收集而设计,涵盖了患者基线特征、日常评估及结果指标。数据通过结构化MicrosoftExcel数据库进行管理,遵循双重独立录入、自动逻辑/范围检查和数据管理员一致性验证的规程。所有查询均通过追溯至原始CRF来解决,最终分析数据集由首席研究员进行审查和锁定。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

This study utilizes a standardized paper Case Report Form designed specifically for data collection, encompassing patient baseline characteristics, daily assessments, and outcome measures. Data are managed via a structured Microsoft Excel database, following a protocol of dual independent entry, automated logic/range checks, and consistency verification by a data manager. All queries are resolved by tracing back to the original CRF, and the final analysis dataset is reviewed and locked by the principal investigator.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-03-02 11:25:21